

CANCER GENOMICS & PROTEOMICS

www.iar-anticancer.org, www.iarjournals.org

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004), VOL. 2 (2005), VOL. 3 (2006), VOL. 4 (2007),
VOL. 5 (2008), VOL. 6 (2009), VOL. 7 (2010), VOL. 8 (2011)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our websites www.iar-anticancer.org and www.iarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iar-anticancer.org (Editorial Office); IAR websites: www.iar-anticancer.org and www.iarjournals.org

Free specimen copies of CGP are available on request.

A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNYTSKYI (*Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, QLD, Australia*)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DU-QUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (*Columbia, SC; St. Louis, MO, USA*)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (*Munich, Germany*)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (*Norcross, GA, USA; Guangzhou, P.R. China*)

TGF- β 1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad; Stockholm; Sweden; Mumbai, India*)

Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, Y. KAWASHIMA, K. YOSHIO, J.-I. ISHII, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU (*Kanagawa, Japan*)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O'MEARA, S. CRUET-HENNEQUART, M.P. CARTY (*Galway, Ireland*)

Identification of Melanoma Antigens Using a Serological Proteome Approach (SERPA). A. SUZUKI, A. IIZUKA, M. KOMIYAMA, M. TAKIKAWA, A. KUME, S. TAI, C. OHSHITA, A. KURUSU, Y. NAKAMURA, A. YAMAMOTO, N. YAMAZAKI, S. YOSHIKAWA, Y. KIYOHARA, Y. AKIYAMA (*Shizuoka; Tokyo; Saitama, Japan*)

DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S.ET. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (*Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA*)

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRÜCK, G. PEREIRA, T. EFFERTH (*Heidelberg; Mainz, Germany*)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (*Regensburg; Munich, Germany*)

In Vivo Testing of ¹⁷⁷ Lu-Labelled Anti-PSMA Antibody as a New Radioimmunotherapeutic Agent Against Prostate Cancer. M. BEHE, K. ALT, F. DEININGER, P. BÜHLER, U. WETTERAUER, W.A. WEBER, U. ELSÄSSER-BEILE, P. WOLF (<i>Freiburg, Germany</i>)	55
Bispecific Oligonucleotides May Induce Interferon Expression in LNCaP Cells Enhancing Surface Antigen Expression: Effect of Intrastrand Base Pair Complementarity. M. RUBENSTEIN, C.M.P. HOLLOWELL, P. GUINAN (<i>Chicago, IL, USA</i>)	61
ALDH Activity Indicates Increased Tumorigenic Cells, But Not Cancer Stem Cells, in Prostate Cancer Cell Lines. C. YU, Z. YAO, J. DAI, H. ZHANG, J. ESCARA-WILKE, X. ZHANG, E.T. KELLER (<i>Ann Arbor, MI, USA; Tianjin, PR China</i>).....	69
Role of Amifostine on Acute and Late Radiation Nephrotoxicity: A Histopathological Study. M. KANTER, Y. TOPCU-TARLADACALISIR, C. UZAL (<i>Edirne, Turkey</i>)	77
Geraniol Rescues Inflammation in Cellular and Animal Models of Mevalonate Kinase Deficiency. A. MARCUZZI, S. CROVELLA, A. PONTILLO (<i>Trieste, Italy; Recife, Pernambuco, Brazil</i>).....	87
Effect of CO ₂ Laser Irradiation on Hormesis Induction in Cultured Oral Cells. K. IWASAKA, K. TOMITA, Y. OZAWA, T. KATAYAMA, H. SAKAGAMI (<i>Sakado, Saitama, Japan</i>)	93
Increased In Vivo Efficacy of Lenalidomide by Addition of Piroctone Olamine. Y. KIM, P. ALPMANN, S. BLAUM-FEDER, S. KRÄMER, T. ENDO, D. LU, D. CARSON, I.G.H. SCHMIDT-WOLF (<i>Bonn, Germany; La Jolla, CA, USA; Sapporo, Hokkaido, Japan</i>)	99
<i>Clinical Studies</i>	
The Length of Peritoneal Surgical Manipulation Correlates with Serum CA 125 Levels. E. PASQUAL, S. BACCHETTI, G. MORABITO, S. BERTOZZI, P.P. CAGOL, D. DE ANNA (<i>Udine, Italy</i>)	105
Beck Depression Inventory (BDI) in Patients with Breast Disease and Breast Cancer: A Prospective Case-Control Study. M. ESKELINEN, P. OLLONEN (<i>Kuopio, Finland</i>)	111
Use of Flashlamp-Pumped Pulsed Dye Laser in the Treatment of Superficial Vascular Malformations and Ulcerated Hemangiomas. L. DI MAIO, A. BALDI, V. DIMAIO, A. BARZI (<i>Chieti; Naples; Rome, Italy</i>).....	117
Unicystic Ameloblastoma of the Mandible. D. MENDITTI, L. LAINO, G. DE MARCO, A. DE ROSA, P. MELLONE, A. BALDI (<i>Naples, Italy</i>).....	125
Technological Improvements in the Treatment of Haemorrhoids and Obstructed Defaecation Syndrome. G. REBOA, M. GIPPONI, T. TESTA, F. LANTIERI (<i>Genoa, Italy</i>).....	129
An Easy Method to Highlight Chief Cells in Gastric Biopsies. C.A. RUBIO (<i>Stockholm, Sweden</i>).....	137
Mid-trimester Amniotic Fluid Interleukins (IL-1 β , IL-10 and IL-18) as Possible Predictors of Preterm Delivery. K. PUCHNER, C. IAVAZZO, D. GOURGIOTIS, M. BOUTSIKOU, S. BAKA, D. HASSIAKOS, E. KOUSKOUNI, E. ECONOMOU, A. MALAMITSI-PUCHNER, G. CREATSAS (<i>Athens, Greece</i>).....	141

* Review (page 11)